Australian officials mum on details of drug stockpile purchase

06/3/2004 | Australian (tiered subscription model), The

The Australian government cited national security considerations in refusing to release details of its no-bid, multi-million dollar purchase of an antiviral medicine stockpile for use in case of a flu pandemic. The government decided to purchase Tamiflu, rather than Relenza, which was developed by Biota, a small Melbourne biotech firm. Biota has filed suit against GlaxoSmithKline, alleging the company failed to adequately promote Relenza under a licensing agreement.

View Full Article in:

Australian (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY